AP804A - APO-B-secretion/MTP inhibitory amides. - Google Patents

APO-B-secretion/MTP inhibitory amides. Download PDF

Info

Publication number: AP804A
Authority: AP; ARIPO
Prior art keywords: inhibitors; compounds; crc10; alkyl; crc4
Prior art date: 1996-11-27

Application number

APAP/P/1997/001145A

Other languages

English (en)

Other versions

AP9701145A0 (en

Inventor

George Chang

George J Quallich

Original Assignee

Pfizer

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-11-27

Filing date

1997-11-20

Publication date

2000-01-28

1997-11-20 Application filed by Pfizer filed Critical Pfizer

1998-01-31 Publication of AP9701145A0 publication Critical patent/AP9701145A0/xx

2000-01-28 Application granted granted Critical

2000-01-28 Publication of AP804A publication Critical patent/AP804A/en

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
- C07D217/04—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Health & Medical Sciences (AREA)
Diabetes (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Obesity (AREA)
Hematology (AREA)
Cardiology (AREA)
Emergency Medicine (AREA)
Endocrinology (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Child & Adolescent Psychology (AREA)
Heart & Thoracic Surgery (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Plural Heterocyclic Compounds (AREA)
Indole Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Other In-Based Heterocyclic Compounds (AREA)

APAP/P/1997/001145A 1996-11-27 1997-11-20 APO-B-secretion/MTP inhibitory amides. AP804A (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US3230796P	1996-11-27	1996-11-27
PCT/IB1997/001368 WO1998023593A1 (en)	1996-11-27	1997-11-03	Apo b-secretion/mtp inhibitory amides

Publications (2)

Publication Number	Publication Date
AP9701145A0 AP9701145A0 (en)	1998-01-31
AP804A true AP804A (en)	2000-01-28

Family

ID=21864233

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
APAP/P/1997/001145A AP804A (en)	1996-11-27	1997-11-20	APO-B-secretion/MTP inhibitory amides.

Country Status (34)

Country	Link
US (1)	US6121283A (is)
EP (1)	EP0944602A1 (is)
JP (1)	JP3270764B2 (is)
KR (1)	KR100334567B1 (is)
CN (2)	CN1238764A (is)
AP (1)	AP804A (is)
AR (1)	AR010309A1 (is)
AU (1)	AU716151B2 (is)
BG (2)	BG108830A (is)
BR (1)	BR9714364A (is)
CA (1)	CA2272719C (is)
CZ (1)	CZ292160B6 (is)
DZ (1)	DZ2358A1 (is)
EA (1)	EA001539B1 (is)
GT (1)	GT199700122A (is)
HN (1)	HN1997000144A (is)
HR (1)	HRP970642A2 (is)
ID (1)	ID18995A (is)
IL (1)	IL129744A0 (is)
IS (1)	IS5040A (is)
MA (1)	MA26451A1 (is)
NO (1)	NO312760B1 (is)
NZ (1)	NZ335162A (is)
OA (1)	OA11050A (is)
PA (1)	PA8441601A1 (is)
PE (1)	PE17199A1 (is)
SK (1)	SK65499A3 (is)
TN (1)	TNSN97193A1 (is)
TR (1)	TR199901180T2 (is)
TW (1)	TW502023B (is)
UY (1)	UY24789A1 (is)
WO (1)	WO1998023593A1 (is)
YU (1)	YU23499A (is)
ZA (1)	ZA9710641B (is)

Families Citing this family (98)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6262277B1 (en)	1994-09-13	2001-07-17	G.D. Searle And Company	Intermediates and processes for the preparation of benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
US6642268B2 (en)	1994-09-13	2003-11-04	G.D. Searle & Co.	Combination therapy employing ileal bile acid transport inhibiting benzothipines and HMG Co-A reductase inhibitors
DK0832069T3 (da) *	1995-06-07	2003-04-22	Pfizer	Biphenyl-2-carboxylsyre-tetrahydroisoquinolin-6-ylamidderivater, deres fremstilling og deres anvendelse som inhibitorer af sekretion af mikrosomalt triglyceridoverførselsprotein og/eller apolipoprotein B (Apo B)
GB9708805D0 (en)	1997-05-01	1997-06-25	Smithkline Beecham Plc	Compounds
US5968950A (en) *	1997-06-23	1999-10-19	Pfizer Inc	Apo B-secretion/MTP inhibitor hydrochloride salt
GB9810876D0 (en)	1998-05-20	1998-07-22	Smithkline Beecham Plc	Compounds
US6288234B1 (en)	1998-06-08	2001-09-11	Advanced Medicine, Inc.	Multibinding inhibitors of microsomal triglyceride transferase protein
WO2000021951A1 (en)	1998-10-08	2000-04-20	Smithkline Beecham Plc	Tetrahydrobenzazepine derivatives useful as modulators of dopamine d3 receptors (antipsychotic agents)
GB9826412D0 (en)	1998-12-03	1999-01-27	Glaxo Group Ltd	Chemical compounds
JP2002533412A (ja) *	1998-12-23	2002-10-08	ジー．ディー．サールエルエルシー	心臓血管に適用するための回腸胆汁酸輸送阻害剤およびコレステリルエステル転送タンパク質阻害剤の組み合わせ
KR20020002367A (ko) *	1998-12-23	2002-01-09	윌리암스 로저 에이	심혈관 징후를 위한 조합물
WO2000038721A1 (en)	1998-12-23	2000-07-06	G.D. Searle Llc	Combinations of cholesteryl ester transfer protein inhibitors and nicotinic acid derivatives for cardiovascular indications
DE19929065A1 (de) *	1999-06-25	2000-12-28	Bayer Ag	Kombination von MTP-Inhibitoren und HMG-CoA-Reduktase-Inhibitoren und ihre Verwendung in Arzneimitteln
DE19929012A1 (de) *	1999-06-25	2000-12-28	Bayer Ag	Kombination von MTP-Inhibitoren und stoffwechselbeeinflussenden Wirkstoffen und ihre Verwendung in Arzneimitteln
DE19929031A1 (de) *	1999-06-25	2000-12-28	Bayer Ag	Kombination von MTP-Inhibitoren und Lipidsenkern und ihre Verwendung in Arzneimitteln
AU6824700A (en) *	1999-07-20	2001-02-05	Novartis Ag	Organic compounds
IL139449A0 (en) *	1999-11-10	2001-11-25	Pfizer Prod Inc	Use of apo b secretion/mtp inhibitors
CA2324801A1 (en) *	1999-11-10	2001-05-10	Andrew Gordon Swick	Use of apo b secretion/mtp inhibitors and anti-obesity agents
CA2324800A1 (en) *	1999-11-10	2001-05-10	Mary Anne Hickman	Use of apo b secretion/mtp inhibitors
IL139450A0 (en) *	1999-11-10	2001-11-25	Pfizer Prod Inc	Methods of administering apo b-secretion/mtp inhibitors
ES2240420T3 (es)	2000-01-18	2005-10-16	Novartis Ag	Carboxamidas utiles como inhibidores de la proteina de transferencia de trigliceridos microsomicos y de la secrecion de apolipoproteina b.
BRPI0109200B8 (pt)	2000-03-14	2021-05-25	Actelion Pharmaceuticals Ltd	compostos e composições farmacêuticas
AU2001262185A1 (en) *	2000-04-10	2001-10-23	Novartis Ag	Substituted (hetero)aryl carboxamide derivatives as microsomal triglyceride transfer protein (mtp) and apolipoprotein b (apo b) secretion
GB0013383D0 (en) *	2000-06-01	2000-07-26	Glaxo Group Ltd	Therapeutic benzamide derivatives
GB0013346D0 (en) *	2000-06-01	2000-07-26	Glaxo Group Ltd	Therapeutic benzamide derivatives
WO2002014276A1 (en) *	2000-08-10	2002-02-21	Tanabe Seiyaku Co., Ltd.	Benzoylaminoisoindoline compounds, processes for the preparation of the same and intermediates for the synthesis thereof
WO2002014277A1 (en) *	2000-08-10	2002-02-21	Tanabe Seiyaku Co., Ltd.	Biphenylcarboxamidoisoindoline compounds, processes for the preparation of the same and intermediates for the synthesis thereof
WO2002020009A1 (en) *	2000-09-01	2002-03-14	Sankyo Company, Limited	Medicinal compositions
JO2654B1 (en)	2000-09-04	2012-06-17	شركة جانسين فارماسوتيكا ان. في	Multiple aryl caroxa amides are useful as lipid - lowering agents
CN1478077A (zh) *	2000-10-05	2004-02-25	��ҩƷ��ҵ��ʽ��	作为apo b分泌抑制剂的苯甲酰胺化合物
JO2409B1 (en)	2000-11-21	2007-06-17	شركة جانسين فارماسوتيكا ان. في	Second-phenyl carboxy amides are useful as lipid-lowering agents
US20040157866A1 (en) *	2001-04-30	2004-08-12	Hisashi Takasugi	Amide compounds
JP2004534812A (ja) *	2001-06-22	2004-11-18	ファイザー・プロダクツ・インク	薬物および中性ポリマーの分散物の医薬組成物
KR100575944B1 (ko) *	2001-06-28	2006-05-02	화이자 프로덕츠 인코포레이티드	미소체 트리글리세라이드 전달 단백질(ｍｔｐ) 및/또는아포지방단백질 ｂ(ａｐｏｂ)분비의 억제제로서의트리아미드-치환된 인돌, 벤조푸란 및 벤조티오펜
WO2003007888A2 (en) *	2001-07-20	2003-01-30	Adipogenix, Inc.	Fat accumulation-modulating compounds
WO2003013516A1 (en) *	2001-08-10	2003-02-20	Adipogenix, Inc.	Fat accumulation-modulating compounds
US20050038035A1 (en) *	2001-11-28	2005-02-17	Hisashi Takasugi	Heterocyclic amide compounds as apolipoprotein b inhibitors
US6852753B2 (en)	2002-01-17	2005-02-08	Pharmacia Corporation	Alkyl/aryl hydroxy or keto thiepine compounds as inhibitors of apical sodium co-dependent bile acid transport (ASBT) and taurocholate uptake
PL372247A1 (en)	2002-02-01	2005-07-11	Pfizer Products Inc.	Method for making homogeneous spray-dried solid amorphous drug dispersions utilizing modified spray-drying apparatus
EP1479666A4 (en) *	2002-02-28	2010-10-13	Japan Tobacco Inc	ESTER CONNECTION AND THEIR MEDICAL USE
CA2478909A1 (en) *	2002-03-13	2003-09-25	Duane D. Miller	Substituted tetrahydroisoquinoline compounds, methods of making, and their use
WO2004039795A2 (en) *	2002-10-29	2004-05-13	Fujisawa Pharmaceutical Co., Ltd.	Amide compounds for the treatment of hyperlipidemia
MXPA05006744A (es) *	2002-12-20	2005-09-08	Pfizer Prod Inc	Inhibidores de la proteina microsomal de transferencia de trigliceridos.
CA2510815A1 (en) *	2002-12-20	2004-07-08	Pfizer Products Inc.	Microsomal triglyceride transfer protein inhibitors
WO2004082675A1 (en)	2003-03-17	2004-09-30	Japan Tobacco Inc.	Method for increasing the oral bioavailability of s-[2- ([[1- (2-ethylbutyl) cyclohexyl] carbonyl] amino) phenyl] 2-methylpropanethioate
JP4832897B2 (ja)	2003-08-29	2011-12-07	日本たばこ産業株式会社	エステル誘導体及びその医薬用途
CA2557163C (en)	2004-03-01	2011-08-16	Idorsia Pharmaceuticals Ltd	Substituted 1,2,3,4-tetrahydroisoquinoline derivatives
KR101494067B1 (ko)	2004-03-05	2015-02-16	더 트러스티스 오브 더 유니버시티 오브 펜실바니아	부작용을 최소화하면서 과지질혈증 및 과콜레스테롤혈증과 연관된 질환 또는 질병의 치료 방법
US7262318B2 (en) *	2004-03-10	2007-08-28	Pfizer, Inc.	Substituted heteroaryl- and phenylsulfamoyl compounds
US20050288340A1 (en) *	2004-06-29	2005-12-29	Pfizer Inc	Substituted heteroaryl- and phenylsulfamoyl compounds
US20060030623A1 (en) *	2004-07-16	2006-02-09	Noboru Furukawa	Agent for the treatment or prevention of diabetes, obesity or arteriosclerosis
US8101774B2 (en)	2004-10-18	2012-01-24	Japan Tobacco Inc.	Ester derivatives and medicinal use thereof
KR20070072888A (ko) *	2004-10-25	2007-07-06	니뽄 다바코 산교 가부시키가이샤	용해성 및 안정성이 개선된 고형 제제 및 그의 제조 방법
CA2588087A1 (en) *	2004-11-15	2006-05-18	Obe Therapy Biotechnology S.A.S.	Methods of reducing body fat
AP2007003979A0 (en)	2004-11-23	2007-06-30	Warner Lambert Co	7-(2h-pyrazol-3-yl)-3,5-dihyroxy-heptanoic acid derivatives as hmg co-a reductase inhibitors for thetreatment of lipidemia
JP2006249022A (ja)	2005-03-11	2006-09-21	Sumitomo Chemical Co Ltd	４−（２−メチルフェニル）ベンゾトリフルオライドの製造方法
BRPI0607555A2 (pt)	2005-04-19	2009-09-15	Surface Logix Inc	inibidores da proteìna microssomal de transferência de triglicirideo e secreção de apo-b
EP1890767A2 (en) *	2005-05-27	2008-02-27	Pfizer Products Inc.	Combination of a cannabinoid-1- receptor-antagonist and a microsomal triglyceride transfer protein inhibitor for treating obesity or mainataining weight loss
US7741317B2 (en)	2005-10-21	2010-06-22	Bristol-Myers Squibb Company	LXR modulators
US7888376B2 (en)	2005-11-23	2011-02-15	Bristol-Myers Squibb Company	Heterocyclic CETP inhibitors
US8383660B2 (en)	2006-03-10	2013-02-26	Pfizer Inc.	Dibenzyl amine compounds and derivatives
US7919506B2 (en)	2006-03-10	2011-04-05	Pfizer Inc.	Dibenzyl amine compounds and derivatives
AU2007225273A1 (en) *	2006-03-10	2007-09-20	Neurogen Corporation	Piperazinyl oxoalkyl tetrahydroisoquinolines and related analogues
SG10201406016SA (en) *	2006-04-03	2014-11-27	Stella Aps	Pharmaceutical composition comprising anti-mirna antisense oligonucleotides
EP2007888A2 (en)	2006-04-03	2008-12-31	Santaris Pharma A/S	Pharmaceutical composition comprising anti-mirna antisense oligonucleotides
CA2654183A1 (en) *	2006-06-02	2007-12-13	San Diego State University Research Foundation	Compositions and methods for ameliorating hyperlipidemia
US20090042835A1 (en) *	2006-06-02	2009-02-12	Davis Roger A	Compositions and methods for ameliorating hyperlipidemia
CA2666191C (en) *	2006-10-09	2017-07-11	Santaris Pharma A/S	Rna antagonist compounds for the modulation of pcsk9
AR063275A1 (es) *	2006-10-12	2009-01-14	Epix Delaware Inc	Compuestos de carboxamida, una composicion farmaceutica que los comprende y su uso en la preparacion de un medicamento para el tratamiento de enfermedades mediadas por la activacion de ccr2.
BRPI0717314A2 (pt) *	2006-10-24	2014-01-21	Janssen Pharmaceutica Nv	Derivados de ácido tetra-hidro-naftaleno-1-carboxílico inibidores de mtp
JO2653B1 (en)	2006-10-24	2012-06-17	شركة جانسين فارماسوتيكا ان. في	Tetrahydroflavin 1-carboxylic acid substituted with pyridine or pyrazine inhibit MTB
CN101663262B (zh)	2006-12-01	2014-03-26	百时美施贵宝公司	用于治疗动脉粥样硬化和心血管疾病的作为cetp抑制剂的n-(3-苄基)-2,2-(二苯基)-丙-1胺衍生物
WO2008075949A1 (en) *	2006-12-20	2008-06-26	Friesland Brands B.V.	Modulation of human microsomal triglyceride transfer protein (mtp or mttp) gene expression by food-grade/ingested dietary microorganisms
JP2010513534A (ja) *	2006-12-21	2010-04-30	エージェリオンファーマシューティカルズ，インコーポレイテッド	Ｍｔｐインヒビターおよびコレステロール吸収インヒビターを含む組み合わせを用いて肥満症を処置する方法
DK2149605T3 (da) *	2007-03-22	2013-09-30	Santaris Pharma As	Korte RNA antagonist forbindelser til modulering af det ønskede mRNA
US8470791B2 (en) *	2007-03-22	2013-06-25	Santaris Pharma A/S	RNA antagonist compounds for the inhibition of Apo-B100 expression
CA2690748A1 (en) *	2007-06-25	2008-12-31	Neurogen Corporation	Piperazinyl oxoalkyl tetrahydro-beta-carbolines and related analogues
JP2010537958A (ja) *	2007-08-30	2010-12-09	サンタリスファーマアー／エス	Ｆａｂｐ４／ａｐ２を調節するためのｒｎａアンタゴニスト化合物
EP2623599B1 (en) *	2007-10-04	2019-01-02	Roche Innovation Center Copenhagen A/S	Micromirs
HRP20160569T1 (hr)	2007-12-03	2016-07-29	Obe Therapy Biotechnology	Boropeptidni inhibitori enteropeptidaze i njihove uporabe u liječenju pretilosti, pretjerane tjelesne težine i/ili bolesti povezane s abnormalnim metabolizmom masti
BRPI0820701A2 (pt)	2007-12-11	2015-06-16	Cytopathfinder Inc	Composto de carboxamida e seu uso como agonistas do receptor de quimiocina
US20090197947A1 (en) *	2008-02-01	2009-08-06	The Research Foundation Of State University Of New York	Medicaments and methods for lowering plasma lipid levels and screening drugs
CA2717792A1 (en) *	2008-03-07	2009-09-11	Santaris Pharma A/S	Pharmaceutical compositions for treatment of microrna related diseases
WO2010012667A1 (en)	2008-08-01	2010-02-04	Santaris Pharma A/S	Micro-rna mediated modulation of colony stimulating factors
ES2599979T3 (es) *	2009-04-24	2017-02-06	Roche Innovation Center Copenhagen A/S	Composiciones farmacéuticas para el tratamiento de pacientes de VHC que no responden al interferón
EP2456870A1 (en)	2009-07-21	2012-05-30	Santaris Pharma A/S	Antisense oligomers targeting pcsk9
EP2986599A1 (en)	2013-04-17	2016-02-24	Pfizer Inc.	N-piperidin-3-ylbenzamide derivatives for treating cardiovascular diseases
HUE048738T2 (hu)	2013-06-27	2020-08-28	Roche Innovation Ct Copenhagen As	Antiszensz oligomerek és konjugátumok, amelyek a PCK9-t célozzák meg
WO2015065595A1 (en)	2013-10-30	2015-05-07	Trustees Of Dartmouth College	Method for selectively inhibiting acat1 in the treatment of obesity, metabolic syndrome, and atherosclerosis
WO2016055901A1 (en)	2014-10-08	2016-04-14	Pfizer Inc.	Substituted amide compounds
AU2015335980A1 (en) *	2014-10-22	2017-05-18	Guangzhou Institutes Of Biomedicine And Health, Chinese Academy Of Sciences	Small-molecule inhibitors targeting discoidin domain receptor 1 and uses thereof
BR112021013807A2 (pt)	2019-01-18	2021-11-30	Astrazeneca Ab	Inibidores de pcsk9 e seus métodos de uso
CA3186856A1 (en)	2020-07-29	2022-02-03	Ruth NALLEN	Lomitapide for use in methods of treating hyperlipidemia and hypercholesterolemia in pediatric patients
US20240217967A1 (en) *	2021-03-26	2024-07-04	Chiesi Farmaceutici S.P.A.	Indoline derivatives as ddrs inhibitors
US20240190847A1 (en) *	2021-03-26	2024-06-13	Chiesi Farmaceutici S.P.A.	Indoline derivatives as ddr1 and ddr2 inhibitors
CN113292493A (zh) *	2021-06-23	2021-08-24	上海立科化学科技有限公司	5,7-二氯-1,2,3,4-四氢异喹啉的制备方法
WO2024216197A2 (en) *	2023-04-13	2024-10-17	Acelot, Inc.	Compounds and methods for treating protein aggregation diseases
US12453728B1 (en)	2024-08-08	2025-10-28	Redux Therapeutics, Llc	Compositions comprising inhibitors of microsomal triglyceride transfer protein and Apo-B secretion

Citations (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4022900A (en) *	1970-09-09	1977-05-10	Marion Laboratories, Inc.	Compositions containing 1,2,3,4-tetrahydroisoquinolines used as hypotensive agents
EP0643057A1 (en) *	1993-09-03	1995-03-15	Bristol-Myers Squibb Company	Inhibitors of microsomal triglyceride transfer protein
WO1996026205A1 (en) *	1995-02-21	1996-08-29	Bristol-Myers Squibb Company	Inhibitors of microsomal triglyceride transfer protein and method

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1996040640A1 (en) *	1995-06-07	1996-12-19	Pfizer Inc.	BIPHENYL-2-CARBOXYLIC ACID-TETRAHYDRO-ISOQUINOLIN-6-YL AMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN AND/OR APOLIPOPROTEIN B (Apo B) SECRETION

1997
- 1997-11-03 EA EA199900416A patent/EA001539B1/ru not_active IP Right Cessation
- 1997-11-03 YU YU23499A patent/YU23499A/sh unknown
- 1997-11-03 EP EP97945048A patent/EP0944602A1/en not_active Withdrawn
- 1997-11-03 KR KR1019997004662A patent/KR100334567B1/ko not_active Expired - Fee Related
- 1997-11-03 US US09/284,466 patent/US6121283A/en not_active Expired - Fee Related
- 1997-11-03 JP JP52446498A patent/JP3270764B2/ja not_active Expired - Fee Related
- 1997-11-03 CN CN97180033A patent/CN1238764A/zh active Pending
- 1997-11-03 SK SK654-99A patent/SK65499A3/sk unknown
- 1997-11-03 TR TR1999/01180T patent/TR199901180T2/xx unknown
- 1997-11-03 BR BR9714364A patent/BR9714364A/pt not_active Application Discontinuation
- 1997-11-03 NZ NZ335162A patent/NZ335162A/xx unknown
- 1997-11-03 WO PCT/IB1997/001368 patent/WO1998023593A1/en not_active Ceased
- 1997-11-03 CA CA002272719A patent/CA2272719C/en not_active Expired - Fee Related
- 1997-11-03 AU AU46347/97A patent/AU716151B2/en not_active Ceased
- 1997-11-03 IL IL12974497A patent/IL129744A0/xx unknown
- 1997-11-04 HN HN1997000144A patent/HN1997000144A/es unknown
- 1997-11-05 TW TW086116476A patent/TW502023B/zh not_active IP Right Cessation
- 1997-11-14 PA PA84416A patent/PA8441601A1/es unknown
- 1997-11-20 AP APAP/P/1997/001145A patent/AP804A/en active
- 1997-11-24 PE PE1997001062A patent/PE17199A1/es not_active Application Discontinuation
- 1997-11-25 UY UY24789A patent/UY24789A1/es not_active Application Discontinuation
- 1997-11-25 ID IDP973763A patent/ID18995A/id unknown
- 1997-11-25 GT GT199700122A patent/GT199700122A/es unknown
- 1997-11-26 DZ DZ970208A patent/DZ2358A1/xx active
- 1997-11-26 HR HR60/032,307A patent/HRP970642A2/hr not_active Application Discontinuation
- 1997-11-26 ZA ZA9710641A patent/ZA9710641B/xx unknown
- 1997-11-26 AR ARP970105560A patent/AR010309A1/es unknown
- 1997-11-26 TN TNTNSN97193A patent/TNSN97193A1/fr unknown
- 1997-11-26 MA MA24877A patent/MA26451A1/fr unknown
1999
- 1999-04-30 IS IS5040A patent/IS5040A/is unknown
- 1999-05-19 OA OA9900106A patent/OA11050A/en unknown
- 1999-05-26 BG BG108830A patent/BG108830A/bg unknown
- 1999-05-26 NO NO19992525A patent/NO312760B1/no unknown
- 1999-05-26 BG BG103434A patent/BG103434A/xx unknown
2002
- 2002-02-19 CN CN02105189A patent/CN1380289A/zh active Pending
- 2002-09-17 CZ CZ20023137A patent/CZ292160B6/cs not_active IP Right Cessation

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4022900A (en) *	1970-09-09	1977-05-10	Marion Laboratories, Inc.	Compositions containing 1,2,3,4-tetrahydroisoquinolines used as hypotensive agents
EP0643057A1 (en) *	1993-09-03	1995-03-15	Bristol-Myers Squibb Company	Inhibitors of microsomal triglyceride transfer protein
WO1996026205A1 (en) *	1995-02-21	1996-08-29	Bristol-Myers Squibb Company	Inhibitors of microsomal triglyceride transfer protein and method

Also Published As

Publication number	Publication date
US6121283A (en)	2000-09-19
AR010309A1 (es)	2000-06-07
AU716151B2 (en)	2000-02-17
AP9701145A0 (en)	1998-01-31
MA26451A1 (fr)	2004-12-20
TW502023B (en)	2002-09-11
NO992525D0 (no)	1999-05-26
NZ335162A (en)	2000-01-28
BR9714364A (pt)	2000-03-21
CZ292160B6 (cs)	2003-08-13
NO992525L (no)	1999-05-26
HRP970642A2 (en)	1998-10-31
EP0944602A1 (en)	1999-09-29
ID18995A (id)	1998-05-28
KR20000057269A (ko)	2000-09-15
EA001539B1 (ru)	2001-04-23
PE17199A1 (es)	1999-02-19
TR199901180T2 (xx)	1999-08-23
AU4634797A (en)	1998-06-22
HN1997000144A (es)	1997-12-16
OA11050A (en)	2002-03-07
ZA9710641B (en)	1999-05-26
DZ2358A1 (fr)	2002-12-28
CA2272719A1 (en)	1998-06-04
NO312760B1 (no)	2002-07-01
SK65499A3 (en)	2001-05-10
UY24789A1 (es)	2000-09-29
YU23499A (sh)	2001-07-10
PA8441601A1 (es)	2000-05-24
IS5040A (is)	1999-04-30
GT199700122A (es)	1999-05-19
EA199900416A1 (ru)	1999-12-29
TNSN97193A1 (fr)	2005-03-15
BG103434A (en)	2000-07-31
IL129744A0 (en)	2000-02-29
KR100334567B1 (ko)	2002-05-03
CN1380289A (zh)	2002-11-20
WO1998023593A1 (en)	1998-06-04
JP2000505810A (ja)	2000-05-16
CN1238764A (zh)	1999-12-15
CA2272719C (en)	2002-10-01
JP3270764B2 (ja)	2002-04-02
BG108830A (bg)	2005-10-31

Publication	Publication Date	Title
AP804A (en)	2000-01-28	APO-B-secretion/MTP inhibitory amides.
KR101186386B1 (ko)	2012-09-26	Ｓ１ｐ 수용체 결합능을 갖는 화합물 및 그 의약 용도
US6121304A (en)	2000-09-19	Pentafluorobenzenesulfonamides and analogs
RU2618628C1 (ru)	2017-05-05	Производные N-пиперидин-3-илбензамида для лечения сердечно-сосудистых заболеваний
US7291644B2 (en)	2007-11-06	Indole derivatives
EP2593428B1 (en)	2014-11-19	N-sulfonylbenzamides as inhibitors of voltage-gated sodium channels
JP5989923B2 (ja)	2016-09-07	メチル基変更酵素の調節物質、組成物及びその使用
AU2015219920B2 (en)	2018-12-20	Triazine compound and use thereof for medical purposes
PT2004607E (pt)	2012-02-01	Derivados de ácido (4-(4-[6-(trifluorometil-piridin-3- -ilamino)-heteroaril contendo n]-fenil)-ciclo-hexil)- -acético e seus usos farmacêuticos
NZ532080A (en)	2006-08-31	Heterocyclic compounds and methods of use
JP2009513523A (ja)	2009-04-02	ベンゼンスルホニルアミノ化合物およびそれらを含む医薬組成物
EA016345B1 (ru)	2012-04-30	Новые сульфонилпирролы в качестве ингибиторов гдац (гистондезацетилазы)
CA3000431A1 (en)	2017-04-13	Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof
US12258308B2 (en)	2025-03-25	Benzene derivative
US7135495B2 (en)	2006-11-14	Indole derivatives
Gribble et al.	1996	ATP-citrate lyase as a target for hypolipidemic intervention. Design and synthesis of 2-substituted butanedioic acids as novel, potent inhibitors of the enzyme
He et al.	2014	Design, synthesis and molecular docking of amide and urea derivatives as Escherichia coli PDHc-E1 inhibitors
US20160102074A1 (en)	2016-04-14	Substituted amide compounds
KR102860768B1 (ko)	2025-09-17	신장 장애 치료에 사용하기 위한 화합물
Yang et al.	2023	Discovery of Novel N-Hydroxy-1, 2, 4-oxadiazole-5-formamides as ASM Direct Inhibitors for the Treatment of Atherosclerosis
CN1227008C (zh)	2005-11-16	将非cox－2选择性抑制剂的cox抑制化合物转化成为cox－2选择性抑制剂的衍生物的方法
Takahashi et al.	2008	Novel indoline-based acyl-CoA: cholesterol acyltransferase inhibitor with antiperoxidative activity: improvement of physicochemical properties and biological activities by introduction of carboxylic acid
Wang et al.	2011	Synthesis and biological evaluation of ezetimibe analogs as possible cholesterol absorption inhibitors
Cai et al.	2006	Methyl 2-Methoxycarbonyl-3-Phenylpropionate Derivatives: A New Type of Angiotensin Converting Enzyme Inhibitors
HK40011748A (en)	2020-07-17	Amide derivatives as nav1.7 and nav1.8 blockers